The tweet was deleted by the author.
But we saved everything 🙂.
Capricor Therapeutics, Inc. has released its financial results for the fourth quarter and the full year 2025.
The announcement comes as the company prepares for its scheduled quarterly conference call at 4:30 p.m. ET, providing investors and analysts an opportunity to review performance metrics and discuss the outlook for its DMD program and Deramiocel candidate. The company shared links to its detailed financial release and webcast, inviting stakeholders to participate and review its latest operational and financial milestones.
The company's latest financial disclosure follows a period of heightened anticipation around the FDA’s review process for its Duchenne treatment, with the agency having recently set an August 2026 decision deadline as chronicled in Capricor Therapeutics’ ongoing Deramiocel BLA review. This timeline underscores the heightened stakes for investors assessing both short-term results and the broader trajectory of Capricor’s development pipeline.